Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results

Thursday, August 6th, 10:00 a.m. EDT

WALTHAM, Mass., July 30 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that the Company President and Chief Executive
Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on
Thursday, August 6th, 2009 at 10:00 a.m. EDT, to report first quarter fiscal
year 2010 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's
website at www.repligen.com. If you are unable to access the webcast via the
internet, you may also listen to the live broadcast by calling (800) 638-4930
for domestic calls and (617) 614-3944 for international calls. Participants
must provide the following passcode: 65889469. For those who cannot
participate in the live conference call, an archive of the audio webcast will
be available shortly after the call and may be accessed at www.repligen.com.

About Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on the development
of novel therapeutics for neurological disorders. In addition, we are the
world's leading supplier of recombinant Protein A, the sales of which
partially fund the advancement of our development pipeline while supporting
our financial stability. Repligen's corporate headquarters are located at 41
Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional
information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant
to the safe harbor provisions of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
The forward-looking statements in this release do not constitute guarantees of
future performance. Investors are cautioned that statements in this press
release which are not strictly historical statements, including, without
limitation, statements regarding current or future financial performance and
position, management's strategy, plans and objectives for future operations,
plans and objectives for product development, plans and objectives for present
and future clinical trials and results of such trials, plans and objectives
for regulatory approval, litigation, intellectual property, product
development, manufacturing plans and performance such as the anticipated
growth in the monoclonal antibody market and our other target markets and
projected growth in product sales, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and uncertainties
that could cause actual results to differ materially from those anticipated,
including, without limitation, risks associated with: the success of current
and future collaborative relationships, the market acceptance of our products,
our ability to compete with larger, better financed pharmaceutical and
biotechnology companies, new approaches to the treatment of our targeted
diseases, our expectation of incurring continued losses, our uncertainty of
product revenues and profits, our ability to generate future revenues, our
ability to raise additional capital to continue our drug development programs,
the success of our clinical trials, our ability to develop and commercialize
products, our ability to obtain required regulatory approvals, our compliance
with all Food and Drug Administration regulations, our ability to obtain,
maintain and protect intellectual property rights for our products, the risk
of litigation regarding our intellectual property rights, our limited sales
and manufacturing capabilities, our dependence on third-party manufacturers
and value added resellers, our ability to hire and retain skilled personnel,
our volatile stock price, and other risks detailed in Repligen's filings with
the Securities and Exchange Commission. Repligen assumes no obligation to
update any forward-looking information contained in this press release or with
respect to the announcements described herein.

SOURCE Repligen Corporation

Laura Whitehouse, Vice President, Market Development of Repligen Corporation,
+1-781-419-1812